Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database
This study provides new insights into the monitoring, surveillance, and management of cabozantinib-related adverse drug reactions and provides a comprehensive long-term post-marketing safety assessment of cabozantinib.
Authors
- Fu‐Chun Zheng (ORCID: https://orcid.org/0000-0003-3184-3054)
- Xiaoqiang Liu (ORCID: https://orcid.org/0000-0003-4459-2506)
- Sheng Li (ORCID: https://orcid.org/0000-0003-1205-8632)
- Zhipeng Wang (ORCID: https://orcid.org/0000-0002-1145-234X)
- Lei Zhang (ORCID: https://orcid.org/0000-0003-2343-084X)
- Situ Xiong (ORCID: https://orcid.org/0009-0001-5795-3684)
- Jun Deng (ORCID: https://orcid.org/0000-0003-0547-4953)
- Liangwei Wan
- Chen Wang (ORCID: https://orcid.org/0009-0004-4302-2565)
Institutions
- Nanchang University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1080/14740338.2024.2429475
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Nanchang University